Delivery Order SPE2DB22D1002-SPE2DB24FKVN1

Award Date 12/18/23
Potential Completion Date 12/19/23
Potential Value $3.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $5,513.06, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product, with a final completion date of November 16, 2023. This is a delivery order contract with a firm fixed-price pricing type. The contract was not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant...
This federal contract award, valued at $191,397.57, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product, with a completion date of September 26, 2024. This contract is a Firm Fixed Price Delivery Order, and there is no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $76,646.81 firm fixed-price delivery order is for the supply of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product. The contract has an ultimate completion date of February 19, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, valued at $51,402.65, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a Firm Fixed Price Delivery Order to provide NURTEC ODT 75 MG TABLET 8S, a medication. The contract has an ultimate completion date of November 21, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026, which...
This federal contract award, valued at $14,881.06, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of NURTEC ODT 75 MG TABLET 8S, a medication, to support military healthcare programs. The contract is a Firm Fixed Price Delivery Order with a completion date of November 25, 2024. The contract is not designated as a set-aside and was awarded through open competition. AmerisourceBergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of NURTEC ODT 75 MG TABLET 8S. The $67,750.79 firm-fixed-price delivery order contract has a completion date of November 12, 2024 and does not have a set-aside designation. AmerisourceBergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $46,670.69 firm fixed-price delivery order is for the supply of NURTEC ODT 75 MG TABLET 8S, a medical product. The contract has an ultimate completion date of February 7, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award, valued at $3,523.93, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product. The contract has an ultimate completion date of March 14, 2022 and utilizes a firm fixed-price delivery order pricing type. This award is a part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $6,176.41 firm fixed-price delivery order is for the supply of NURTEC ODT 75 MG TABLET 8S, a medication. The contract has a period of performance ending on September 16, 2024. While the original solicitation was not provided, this appears to be part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999 with DLA Troop Support...
This federal contract award, valued at $31,630.64, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, which is a delivery order contract of the firm fixed price type, covers the supply of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product. The contract has an ultimate completion date of March 8, 2024 and does not have a set-aside designation, indicating open competition....
  • SPE2DB22D1002
    Indefinite Delivery Contract
  • SPE2DB22D1002-SPE2DB24FKVN1
    Delivery Order

This federal contract award, valued at $3,681.06, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of NURTEC ODT 75 MG TABLET 8S. The contract has a completion date of December 19, 2023 and is a firm fixed-price delivery order. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 5/13/25, 10:19 AM